Journal of Gynecologic Oncology最新文献

{"title":"Is restaging surgery quintessential in suspected early-stage epithelial ovarian cancer? An ancillary study of the Gynecologic Oncology Research Investigators coLLaborAtion study (GORILLA-3002).","authors":"Jung Chul Kim, Eun Jung Yang, A Jin Lee, Woo Yeon Hwang, Suk-Joon Chang, Hee Seung Kim, Namkyeong Kim, Tae Wook Kong, Eun Ji Lee, Joo-Hyuk Son, Dong Hoon Suh, Seung-Hyuk Shim, Eun Ji Nam","doi":"10.3802/jgo.2026.37.e25","DOIUrl":"10.3802/jgo.2026.37.e25","url":null,"abstract":"<p><strong>Objective: </strong>To assess the necessity of restaging surgery for patients with suspected International Federation of Gynecology and Obstetrics (FIGO) stage I-II epithelial ovarian cancer (EOC) following incomplete surgical staging.</p><p><strong>Methods: </strong>This multicenter retrospective study evaluated patients with early-stage EOC referred for restaging. These patients were diagnosed with suspected FIGO stage I-II EOC between January 2007 and November 2022 after incomplete surgical staging, and no residual region was confirmed by radiological evaluation. Progression-free survival (PFS) and overall survival (OS) were examined.</p><p><strong>Results: </strong>Among the 173 patients included in the study, 56 were assigned to the no restaging surgery group, and 117 to the restaging surgery group. After restaging, 23 were upstaged to other main stage. However, PFS and OS were not significantly different between the groups, also, dividing the groups into 4 groups who underwent chemotherapy and those who did not also did not show significant differences. In multivariate analysis, histologic grade independently influenced PFS outcomes.</p><p><strong>Conclusion: </strong>While restaging surgery resulted in upstaging in some patients, it was not associated with significant differences in PFS or OS in this retrospective analysis. However, the omission of any additional treatment warrants careful consideration and further discussion. Nevertheless, the observation that patients who did not undergo restaging surgery but received adjuvant chemotherapy did not show significantly different prognoses highlights the need for further research to establish appropriate treatment strategies tailored to diverse patient contexts.</p>","PeriodicalId":15868,"journal":{"name":"Journal of Gynecologic Oncology","volume":" ","pages":"e25"},"PeriodicalIF":3.7,"publicationDate":"2026-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13009694/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145354946","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Clinical practice guideline for high-risk human papillomavirus testing in cervical cancer screening: a consensus statement from the Korean Society of Gynecologic Oncology.","authors":"Ju-Hyun Kim, Seung-Hyuk Shim, Kyung-Jin Min, Jae-Kwan Lee, Chong Woo Yoo, Min-Jung Kwon, Shin-Wha Lee, Jaeman Bae","doi":"10.3802/jgo.2026.37.e90","DOIUrl":"10.3802/jgo.2026.37.e90","url":null,"abstract":"<p><p>High-risk human papillomavirus (hrHPV) is a necessary cause of cervical cancer, and hrHPV testing has increasingly been recognized as an effective screening tool that overcomes the limitations of cytology-based screening. However, standardized clinical guidance for the use of hrHPV testing in cervical cancer screening has been limited in Korea, resulting in variability in clinical practice. This consensus-based clinical practice guideline was developed under the auspices of the Korean Society of Gynecologic Oncology through multidisciplinary collaboration involving experts in gynecology, pathology, laboratory medicine, and public health. Relevant domestic and international evidence was systematically reviewed, and input from diverse clinical settings was incorporated through four public hearings. Final recommendations were established through expert consensus. The guideline presents four key recommendations: hrHPV testing may be considered for women aged 25 years or older, with a recommended screening interval of 3 to <5 years; screening assays should differentiate HPV genotypes 16 and 18 and detect other high-risk types, with preference given to clinically validated tests; testing should be performed in appropriately equipped settings with standardized specimen handling and reporting, including documentation of HPV 16/18 status in positive cases; and hrHPV testing should be conducted under rigorous internal and external quality control systems. This guideline aims to support consistent and rational implementation of hrHPV testing in cervical cancer screening in Korea.</p>","PeriodicalId":15868,"journal":{"name":"Journal of Gynecologic Oncology","volume":" ","pages":"e90"},"PeriodicalIF":3.7,"publicationDate":"2026-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13009686/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147463452","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Association between resection margin and local recurrence in the treatment of primary squamous cell vulvar carcinoma.","authors":"Hein Hanna, Gasimli Khayal, Rödel Claus, Georgios Chatzikonstantinou","doi":"10.3802/jgo.2026.37.e26","DOIUrl":"10.3802/jgo.2026.37.e26","url":null,"abstract":"<p><strong>Objective: </strong>Our aim was to assess the potential correlation between resection-free margin and local recurrence in the treatment of squamous cell vulvar carcinoma (SCC).</p><p><strong>Methods: </strong>Seventy-five patients with primary SCC of the vulva and adequately follow-up that were operated in our university hospital between January 2008 to December 2018, were retrospectively evaluated with focus on resection-free margin and its impact on local recurrence. Several prognostic factors were analysed for possible correlation.</p><p><strong>Results: </strong>Median patient age and follow-up was 62.8 years and 57.4 months, respectively. Among all patients, 27 (36%) local recurrences were documented, for a median local recurrence-free survival (LRFS) of 68.1 months for patients resected R0 and 65.6 months for those initially R1 resected (p=0.750). There was also no statistically significant difference (p=0.750) when evaluating the LRFS relative to the absence or not of inguinal lymph node involvement, although there was a numerical difference of approximately 17 months (73.9 vs. 57.3 months). For initially R0 resected patients, no significant influence of the resection-free margin in millimeters on LRFS was noted for a median of 58.4 versus 57.3 months for patients with a free margin of 0.1-3 mm and those with a free margin of >3 mm, respectively (p=0.800). Eleven patients received adjuvant chemoradiotherapy, all for nodal inguinal involvement. Among them, 5 patients developed recurrence, while the other 6 remained free of disease.</p><p><strong>Conclusion: </strong>The extend of resection-free margin does not appear to adversely affect LRFS suggesting that smaller margins could be applied to minimize morbidity without compromising local control.</p>","PeriodicalId":15868,"journal":{"name":"Journal of Gynecologic Oncology","volume":" ","pages":"e26"},"PeriodicalIF":3.7,"publicationDate":"2026-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13009695/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145355005","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Development and validation of a prediction model for lymph node metastasis based on molecular typing in clinically early-stage endometrial carcinoma.","authors":"Qiuyue Han, Quanhong Jiang, Jiaqi Xu, Yuan Zhang, Zhuang Li, Yong Zhao, Zhaoyang Zhang, Ziyuan Yang, Helgi B Schiöth, Yawen Zhang, Lingliya Tang, Shuaixin Wang, Beihua Kong, Ruifen Dong","doi":"10.3802/jgo.2026.37.e19","DOIUrl":"10.3802/jgo.2026.37.e19","url":null,"abstract":"<p><strong>Objective: </strong>To develop and externally validate a machine learning-based preoperative model integrating molecular typing and clinical features to predict lymph node metastasis (LNM) in patients with early-stage endometrial carcinoma (EC).</p><p><strong>Methods: </strong>This retrospective study included 465 patients with clinically early-stage EC treated at Qilu Hospital of Shandong University. Tumors were classified into molecular subtypes using The Cancer Genome Atlas-based methods. Least Absolute Shrinkage and Selection Operator regression identified five preoperative predictors: molecular typing (CN-H vs. non-CN-H), histological subtype, depth of myometrial invasion, neutrophil-to-lymphocyte ratio, and CA125 levels. Multiple machine learning algorithms were evaluated, and logistic regression (LR) was selected based on optimal discrimination and clinical applicability. Model performance was assessed using area under the curve (AUC), calibration plots, and decision curve analysis (DCA). A web-based nomogram was developed for clinical use.</p><p><strong>Results: </strong>The LR model demonstrated excellent discrimination, with AUCs of 0.843 in the training cohort and 0.809 in the testing cohort. The CN-H subtype was significantly associated with increased LNM risk. The model enabled effective risk stratification and calibration curves and DCA confirmed the model's accuracy and clinical utility.</p><p><strong>Conclusion: </strong>By integrating molecular and preoperative clinical features, this model offers accurate LNM risk stratification for early-stage EC. It supports clinical decision-making and has been implemented as a user-friendly online tool. Further prospective multicenter validation is warranted.</p>","PeriodicalId":15868,"journal":{"name":"Journal of Gynecologic Oncology","volume":" ","pages":"e19"},"PeriodicalIF":3.7,"publicationDate":"2026-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13009691/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145086209","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Enhancement of circular RNA 0002577 in serum exosomes in patients with endometrial cancer accelerates disease progression via general transcription factor II-I repeat domain-containing 1 (GTF2IRD1).","authors":"Yueying Li, Ya Liu, Jialu Feng, Juan Du, Wenyan Tian, Liping Zhang","doi":"10.3802/jgo.2026.37.e17","DOIUrl":"10.3802/jgo.2026.37.e17","url":null,"abstract":"<p><strong>Objective: </strong>Uterine corpus endometrial carcinoma (UCEC) is a common gynecologic malignancy with poor prognosis in advanced stages. Circular RNA (circRNA) and exosomes have been documented as significant contributors to the advancement of tumor cells, but the specific regulatory mechanisms between them is unclear. Therefore, our study attempts to explore the mechanism between them.</p><p><strong>Methods: </strong>Firstly, we isolated and identified exosomes, and then validated their role in UCEC progression by experiments in vivo and in vitro. Secondly, a human competing endogenous RNA (ceRNA) array was used to identify the circRNA with the most significant differences in expression from serum of UCEC patient, and validated its role in UCEC progression by experiments in vitro. Then, we find the target gene of this circRNA by RNA sequencing, and further clarify the correlation between those and their role in tumor cell progression through experiments in vitro.</p><p><strong>Results: </strong>Serum exosomes in patients with UCEC can promote the progression of UCEC. The human ceRNA array identified that circRNA 0002577 (circ_0002577) was up-regulated and was the most significantly altered circRNA. Moreover, the up-regulated circ_0002577 in exosomes derived from UCEC patients promote proliferation and migration of UCEC. Based on RNA sequencing results, general transcription factor II-I repeat domain-containing 1 (<i>GTF2IRD1</i>) gene was identified as being highly correlated with circ_0002577. Additionally, a positive correlation between circ_0002577 and GTF2IRD1 was confirmed by experiments in vitro.</p><p><strong>Conclusion: </strong>Exosomes promote UCEC progression through circ_0002577 mediated regulation of <i>GTF2IRD1</i>, highlighting the potential therapeutic targets in treatment for UCEC.</p>","PeriodicalId":15868,"journal":{"name":"Journal of Gynecologic Oncology","volume":" ","pages":"e17"},"PeriodicalIF":3.7,"publicationDate":"2026-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13009689/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145086360","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Suppressor of TCR signaling 2 (Sts-2) as a potential immunotherapy target and prognostic biomarker in cervical cancer.","authors":"Yinlong Chen, Qin Chen, Xiaoqing Guo, Qingliang Zheng","doi":"10.3802/jgo.2026.37.e20","DOIUrl":"10.3802/jgo.2026.37.e20","url":null,"abstract":"<p><strong>Objective: </strong>More efficient immune targets are needed for the treatment of cervical cancer. This study aimed to identify potential targets for immunotherapy and prediction in cervical squamous cell carcinoma and endocervical adenocarcinoma (CESC) by conducting bioinformatics analysis and verifying the results with clinical tissue samples.</p><p><strong>Methods: </strong>A retrospective analysis of RNA sequencing data from 304 patients sourced from The Cancer Genome Atlas (TCGA) and another 300 patients from the Gene Expression Omnibus (GEO) was performed to investigate the correlation between suppressor of TCR signaling 2 (Sts-2) expression and clinical parameters in cervical cancer. To authenticate our findings, we utilized a combination of immunohistochemistry, quantitative polymerase chain reaction, and western blotting techniques in a separate cohort consisting of 6 cervical cancer tissue samples.</p><p><strong>Results: </strong>The Sts-2 gene was discovered to be substantially co-expressed with a multitude of immune checkpoint molecules, including programmed cell death protein 1 (r=0.8, p<0.001), TIGIT (r=0.87, p<0.001), LAG3 (r=0.71, p<0.001), and CTLA4 (r=0.74, p<0.001), in CESC patients. Both the TCGA and GEO datasets have independently validated that Sts-2 expression levels significantly correlate with overall survival rates, thus demonstrating its prognostic importance. A single-gene Gene Set Enrichment Analysis indicated that Sts-2 was highly enriched in T cell-related immune pathways. Moreover, using the Tumor Immune Dysfunction and Exclusion algorithm, it was suggested that high Sts-2 expression might predict a more favorable response to immunotherapy.</p><p><strong>Conclusion: </strong>The heightened expression of Sts-2 serves as a dual indicator of elevated T cell content and a favorable prognosis in cervical cancer.</p>","PeriodicalId":15868,"journal":{"name":"Journal of Gynecologic Oncology","volume":" ","pages":"e20"},"PeriodicalIF":3.7,"publicationDate":"2026-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13009699/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145086285","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Trends in the cost of ovarian cancer across phases of care and surgical years in Korea.","authors":"Byeong-Chan Oh, Sun-Kyeong Park, Sokbom Kang","doi":"10.3802/jgo.2026.37.e30","DOIUrl":"10.3802/jgo.2026.37.e30","url":null,"abstract":"<p><strong>Objective: </strong>This study aimed to estimate the medical costs among patients with ovarian cancer across distinct phases of care and surgical years.</p><p><strong>Methods: </strong>This population-based retrospective cohort study identified newly diagnosed ovarian cancer patients who underwent surgery based on nationwide claims data from Korea (2012-2019). Medical costs were categorized into 5 phases: neoadjuvant chemotherapy, surgery, frontline chemotherapy, monitoring, and recurrence. Total and cancer-related costs were analyzed by surgical year on a per patient and per patient per month (PPPM) basis. Per patient costs were estimated for each phase, with up to one year of follow-up per phase, for patients identified between 2013 and 2016. Generalized linear models (GLMs) examined associations between surgical year and cancer-related costs.</p><p><strong>Results: </strong>Among 10,594 patients, median cancer-related costs per patient were highest in the recurrent phase ($20,548), followed by the frontline chemotherapy ($7,005), neoadjuvant chemotherapy ($5,870), surgery ($4,965), and monitoring phases ($1,906). The median surgery phase costs per patient increased from $4,254 in 2013 to $5,676 in 2016; recurrent phase costs increased from $17,289 to $26,750. GLM analysis revealed that per patient and PPPM costs significantly increased over time, particularly in the surgery and recurrent phases. Compared with the cost per patient in 2013, the cost per patient in 2016 was 27% higher for the surgery phase and 49% higher for the recurrent phase.</p><p><strong>Conclusion: </strong>Ovarian cancer-related costs have significantly increased over time, especially in the surgery and recurrent phases, thus highlighting the growing economic burden and the need for cost-effective care strategies.</p>","PeriodicalId":15868,"journal":{"name":"Journal of Gynecologic Oncology","volume":" ","pages":"e30"},"PeriodicalIF":3.7,"publicationDate":"2026-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13009683/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145513033","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Comparison of oncologic outcome of preoveratively presumed low-risk endometrial cancer patients who underwent only bilateral pelvic sentinel lymph node (SLN) removal and those who underwent pelvic lymphadenectomy in addition to bilateral pelvic SLN removal: Turkish Gynecologic Oncology Group (TRSGO-SLN-009).","authors":"Tugan Bese, Sait Sukru Cebi, Salih Taskin, Cagatay Taskiran, Dogan Vatansever, Firat Ortac, Nedim Tokgozoglu, Hasan Turan, İlker Kahramanoglu, Mete Gungor, Faruk Kose, Macit Arvas, Fuat Demirkiran","doi":"10.3802/jgo.2026.37.e23","DOIUrl":"10.3802/jgo.2026.37.e23","url":null,"abstract":"<p><strong>Objective: </strong>We aimed to compare the oncological outcomes of patients with bilateral sentinel lymph nodes (SLNs) detection and removed with those who underwent pelvic lymphadenectomy (PLA) in addition to bilateral SLNs removal.</p><p><strong>Methods: </strong>This multicenter, retrospective study included cases of endometrioid type, grade I-II endometrial cancer, in which bilateral SLNs were detected and removed. Patients who had only bilateral SLNs detected and removed (group I) and patients who had bilateral SLNs detected and removed and subsequent additional bilateral PLA (group II) were included in the evaluation.</p><p><strong>Results: </strong>In group I (n=216), SLN metastasis rate was 5.5% and in group II (n=251), it was 10.3%. The low-volume disease detection rate was 4.6% in group I and 4.8% in group II. In group II, in patients with SLN macrometastasis had also 28.6% non-SLN macrometastasis. No false-negative results occurred in group II. Recurrence was detected 1.8% in group I and 5% in group II; however, there was no significant difference (p=0.083). Disease-free survival and overall survival, were almost same between the groups (hazard ratio [HR]=2.11; 95% confidence interval [CI]=0.681-6.588; p=0.187) and (HR=1.531; 95% CI=0.392-5.975; p=0.537), respectively.</p><p><strong>Conclusion: </strong>SLN mapping, ultrastaging, and immunohistochemical staining can identify low-volume metastases that may not be identified with classic lymphadenectomy and hematoxylin & eosin staining. It has been observed that adding PLA beyond SLN mapping did not provide an additional positive contribution to survival. For endometriod type grade I-II patients, detection of bilateral SLNs in both hemipelvis only, if detectable, is an adequate approach.</p>","PeriodicalId":15868,"journal":{"name":"Journal of Gynecologic Oncology","volume":" ","pages":"e23"},"PeriodicalIF":3.7,"publicationDate":"2026-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13009701/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145354979","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Updated clinical practice guidelines for human papillomavirus vaccination: the Korean Society of Gynecologic Oncology recommendations.","authors":"Hyunji Lim, Se Ik Kim, Kyung-Jin Min, Jae-Kwan Lee, Jae-Weon Kim, Taek Sang Lee","doi":"10.3802/jgo.2026.37.e71","DOIUrl":"10.3802/jgo.2026.37.e71","url":null,"abstract":"<p><p>The Korean Society of Gynecologic Oncology (KSGO) first developed clinical guidelines for the appropriate administration of human papillomavirus (HPV) vaccines tailored to the Korean context in 2016. In 2019, additional guidelines were introduced following the development of the nonavalent HPV vaccine. The 2021 revision included recommendations for vaccination in middle-aged women and men, as well as the potential benefits of vaccination following conization. In this latest revision, the guidelines focus on the necessity of HPV vaccination in middle-aged men, the Society's position on the single-dose schedule recently recommended by the World Health Organization to expand global vaccine coverage, recommendations regarding additional 9-valent vaccination for those previously vaccinated with bivalent or quadrivalent vaccines, and updated scientific evidence supporting the two-dose schedule for adolescents aged 9 to 14 years.</p>","PeriodicalId":15868,"journal":{"name":"Journal of Gynecologic Oncology","volume":" ","pages":"e71"},"PeriodicalIF":3.7,"publicationDate":"2026-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13009690/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147348427","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Long-term survival outcomes of female genital tract rhabdomyosarcoma in children, adolescents and young adults at a national rare disease diagnosis and treatment center in China.","authors":"Jing Zheng, Jie Yang, Xinyang Jin, Kezhen Zhang, Dongyan Cao, Yang Xiang, Jiaxin Yang","doi":"10.3802/jgo.2026.37.e22","DOIUrl":"10.3802/jgo.2026.37.e22","url":null,"abstract":"<p><strong>Objective: </strong>Rhabdomyosarcoma (RMS) is a rare soft-tissue sarcoma mainly affecting children and adolescents. The genitourinary tract is the second common site involved by RMS. We report the therapeutic effects and long-term survival outcomes of female genital tract RMS.</p><p><strong>Methods: </strong>Patients diagnosed with female genital RMS and younger than 25 years old from Peking Union Medical College Hospital between January 1996 and December 2023 were identified. Clinical features, treatment modalities, and survival outcomes were documented. Patient prognosis evaluation was re-evaluated according to the Children's Oncology Group (COG) risk stratification system.</p><p><strong>Results: </strong>A total of 26 patients were included, with a mean age of 8.1 years. The median follow-up duration was 59.3 months. Primary tumor sites were distributed as follows: vagina (n=12), cervix (n=8), vulva (n=2), pelvic region (n=2), uterus (n=1), and subcutaneous perineum (n=1). The COG Risk Stratification System classified 15 patients as low-risk subset 1, 8 as low-risk subset 2, 2 as intermediate-risk, and 1 as high-risk. Nine patients (34.62%) experienced disease recurrence with a median progression free survival of 15.3 months. The disease-specific mortality rate was 26.92% (7/26). Six patients (66.7% of recurrent cases) succumbed to the disease following recurrence, while one stage 4 patient died during initial treatment.</p><p><strong>Conclusion: </strong>Patients diagnosed as RMS in female genital tract in early stage can have relatively good prognosis. Advanced stage and nonstandard primary treatment were related with increased risk of recurrence. Patients with disease recurrence tend to have poor prognoses and higher mortality rates.</p>","PeriodicalId":15868,"journal":{"name":"Journal of Gynecologic Oncology","volume":" ","pages":"e22"},"PeriodicalIF":3.7,"publicationDate":"2026-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13009692/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145040405","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}